498,490 Shares in Upstream Bio, Inc. $UPB Acquired by Walleye Capital LLC

Walleye Capital LLC acquired a new stake in Upstream Bio, Inc. (NASDAQ:UPB) in the 2nd quarter, Holdings Channel reports. The firm acquired 498,490 shares of the company’s stock, valued at approximately $3,450,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of UPB. Jennison Associates LLC purchased a new stake in Upstream Bio during the fourth quarter worth $7,842,000. Pictet Asset Management Holding SA purchased a new position in shares of Upstream Bio in the fourth quarter valued at $20,991,000. UBS Group AG increased its position in shares of Upstream Bio by 563.4% in the fourth quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after buying an additional 1,533,972 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Upstream Bio in the first quarter valued at $1,666,000. Finally, SEB Asset Management AB acquired a new position in shares of Upstream Bio during the 1st quarter worth $7,906,000.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Upstream Bio in a research report on Monday, August 3rd. Truist Financial dropped their target price on shares of Upstream Bio to $25.00 and set a “buy” rating for the company in a report on Tuesday. Wall Street Zen cut shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday. HC Wainwright began coverage on shares of Upstream Bio in a report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, Mizuho reduced their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $29.67.

More Upstream Bio News

Here are the key news stories impacting Upstream Bio this week:

• Positive Sentiment: JPMorgan raised its price target for Upstream Bio (UPB) from $8 to $9 while maintaining a “Neutral” rating. The revised target implies approximately 27.3% upside from the referenced share price, providing a modest positive catalyst despite the unchanged cautious rating. Benzinga article
• Positive Sentiment: HC Wainwright retained its “Buy” rating and $36 price target, indicating substantial potential upside if Upstream Bio’s pipeline and development plans progress successfully. MarketBeat analyst coverage
• Neutral Sentiment: HC Wainwright’s revised forecasts continue to project losses, including estimated 2026 earnings of negative $3.09 per share and negative $0.79 and $0.82 per share for the third and fourth quarters, respectively. The firm’s “Buy” rating remains unchanged, but the estimates point to a lengthy path toward profitability.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026–2030: 2027 to negative $3.31 from negative $3.09, 2028 to negative $3.13 from negative $2.92, 2029 to negative $3.56 from negative $3.35, and 2030 to negative $3.84 from negative $3.42. These broader expected losses may weigh on investor sentiment and offset the benefit of JPMorgan’s target increase. MarketBeat analyst estimates

Upstream Bio Stock Up 2.3%

NASDAQ UPB opened at $7.07 on Friday. Upstream Bio, Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $33.68. The business has a fifty day moving average of $6.81 and a 200-day moving average of $9.90. The stock has a market cap of $387.22 million, a price-to-earnings ratio of -2.44 and a beta of 1.26.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.01. The business had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%. As a group, analysts anticipate that Upstream Bio, Inc. will post -2.87 EPS for the current year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.